Safety of opicapone in the elderly and very elderly population: an analysis of reported events in a global safety database
Clinical Parkinsonism & Related Disorders · 2026 · 15 · 100500
DOI: 10.1016/j.prdoa.2026.100500 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Parkinsonism & Related Disorders, 2026. Verfasst von Taku Hatano und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Older people with Parkinson's disease (PD) are under-represented in clinical trials despite increasing disease burden and complexity. Although opicapone is approved as an adjunct to levodopa, data in elderly populations are limited. This study assessed its real-world safety in the elderly using post-marketing pharmacovigilance data.
Methods
This retrospective analysis used the global opicapone safety database (data-lock: 31 Jan 2026). Valid case safety reports with opicapone as the suspected product were included and classified as elderly (≥65-84 years) or very elderly (≥85 years). Adverse events were analyzed descriptively by system organ class, preferred term, and seriousness. Non-standard use and treatment actions were also assessed.
Results
Among 2914 analyzed cases (2558 elderly; 356 very elderly), 7195 adverse events were reported. Most reported events were non-serious (81.4% of events in elderly cases; 73.5% in very elderly cases). Dyskinesia was the most frequently reported event in both groups (7.1%-7.7% of events), followed by hallucination and visual hallucination (all
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan.
- Wayne State University School of Medicine, Departments of Neurology and Pharmacology, Sastry Foundation Endowed Chair in Parkinson's Disease Research, Detroit, MI, USA.
- Division of Neurology and Gerontology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Iwate, Japan.
- Movement Disorders Unit, Neurology, Hospital Santa Creu i Sant Pau, Universitat Autònoma de Barcelona (Department of Medicine), Barcelona, CIBERNED, Spain.
- BIAL - Portela & C, S.A., Coronado, Portugal.
Zitieren
APA
Hatano, T., LeWitt, P. A., Maeda, T., Mora, J. P., Dias, B. F., Brigas, H. C., Lopes, D., Gama, H., & Holenz, J. (2026). Safety of opicapone in the elderly and very elderly population: an analysis of reported events in a global safety database. Clinical Parkinsonism & Related Disorders, 15, 100500. https://doi.org/10.1016/j.prdoa.2026.100500
Vancouver
Hatano T, LeWitt PA, Maeda T, Mora JP, Dias BF, Brigas HC, et al. Safety of opicapone in the elderly and very elderly population: an analysis of reported events in a global safety database. Clinical Parkinsonism & Related Disorders. 2026;15:100500. doi:10.1016/j.prdoa.2026.100500
BibTeX
@article{Hatano2026,
author = {Hatano, Taku and LeWitt, Peter A and Maeda, Tetsuya and Mora, Javier Pagonabarraga and Dias, Bruno F and Brigas, Helena C and Lopes, Diogo and Gama, Helena and Holenz, Joerg},
title = {Safety of opicapone in the elderly and very elderly population: an analysis of reported events in a global safety database},
journal = {Clinical Parkinsonism & Related Disorders},
year = {2026},
volume = {15},
pages = {100500},
doi = {10.1016/j.prdoa.2026.100500}
}
EUVIMED